As Pfizer Inc. has gained more traction in oncology, the big pharma's strategy in the market has evolved around three anchor brands and smaller "string of pearl" opportunities, management said at a recent press briefing at the company's New York City headquarters.
Pfizer's Oncology Strategy Centers On Three Anchors To Steady The Ship
Ibrance, Xtandi and Bavencio are positioned as three anchor drugs with big market potential and opportunities for expansion, President-Worldwide R&D Mikael Dolsten said at a recent briefing at Pfizer's headquarters.